Advertisement
CERS vs SAFLY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and SAFLY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 0 FA rating(s) are green whileSAFLY’s FA Score has 0 green FA rating(s).
- CERS’s FA Score: 0 green, 5 red.
- SAFLY’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 3 TA indicator(s) are bullish while SAFLY’s TA Score has 0 bullish TA indicator(s).
- CERS’s TA Score: 3 bullish, 6 bearish.
- SAFLY’s TA Score: 0 bullish, 1 bearish.
Price Growth
CERS (@Medical/Nursing Services) experienced а -9.70% price change this week, while SAFLY (@Pharmaceuticals: Other) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.85%. For the same industry, the average monthly price growth was -7.89%, and the average quarterly price growth was +10.85%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.04%. For the same industry, the average monthly price growth was -0.03%, and the average quarterly price growth was +8.71%.
Reported Earning Dates
CERS is expected to report earnings on Feb 19, 2026.
Industries' Descriptions
@Medical/Nursing Services (-4.85% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-2.04% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| CERS | SAFLY | CERS / SAFLY | |
| Capitalization | 286M | 839M | 34% |
| EBITDA | -8.62M | 107M | -8% |
| Gain YTD | -3.247 | 79.372 | -4% |
| P/E Ratio | N/A | 15.38 | - |
| Revenue | 193M | 999M | 19% |
| Total Cash | 78M | 72.6M | 107% |
| Total Debt | 98.9M | 115M | 86% |
CERS | SAFLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 34 | |
SMR RATING 1..100 | 95 | 68 | |
PRICE GROWTH RATING 1..100 | 46 | 36 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (37) in the Medical Specialties industry is in the same range as SAFLY (69) in the null industry. This means that CERS’s stock grew similarly to SAFLY’s over the last 12 months.
SAFLY's Profit vs Risk Rating (34) in the null industry is significantly better than the same rating for CERS (100) in the Medical Specialties industry. This means that SAFLY’s stock grew significantly faster than CERS’s over the last 12 months.
SAFLY's SMR Rating (68) in the null industry is in the same range as CERS (95) in the Medical Specialties industry. This means that SAFLY’s stock grew similarly to CERS’s over the last 12 months.
SAFLY's Price Growth Rating (36) in the null industry is in the same range as CERS (46) in the Medical Specialties industry. This means that SAFLY’s stock grew similarly to CERS’s over the last 12 months.
SAFLY's P/E Growth Rating (100) in the null industry is in the same range as CERS (100) in the Medical Specialties industry. This means that SAFLY’s stock grew similarly to CERS’s over the last 12 months.
| CERS | SAFLY | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 22% |
| Momentum ODDS (%) | 2 days ago 79% | N/A |
| MACD ODDS (%) | 2 days ago 84% | N/A |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 14% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 13% |
| Advances ODDS (%) | 17 days ago 76% | N/A |
| Declines ODDS (%) | 2 days ago 84% | N/A |
| BollingerBands ODDS (%) | 2 days ago 90% | N/A |
| Aroon ODDS (%) | 2 days ago 87% | N/A |
Advertisement
CERS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CERS | 1D Price Change % | ||
|---|---|---|---|---|
| CERS | 100% | -2.61% | ||
| ICUI - CERS | 46% Loosely correlated | -0.36% | ||
| UTMD - CERS | 45% Loosely correlated | -1.29% | ||
| BLFS - CERS | 45% Loosely correlated | +0.08% | ||
| LAB - CERS | 45% Loosely correlated | +2.48% | ||
| PACB - CERS | 44% Loosely correlated | +5.10% | ||
More | ||||
SAFLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SAFLY has been loosely correlated with BIOQ. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SAFLY jumps, then BIOQ could also see price increases.
| Ticker / NAME | Correlation To SAFLY | 1D Price Change % | ||
|---|---|---|---|---|
| SAFLY | 100% | N/A | ||
| BIOQ - SAFLY | 34% Loosely correlated | N/A | ||
| CNVVF - SAFLY | 32% Poorly correlated | N/A | ||
| TCHBF - SAFLY | 29% Poorly correlated | N/A | ||
| LZAGY - SAFLY | 28% Poorly correlated | -1.16% | ||
| CERS - SAFLY | 25% Poorly correlated | -2.61% | ||
More | ||||